Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma - PubMed (original) (raw)
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
C Caldas et al. Nat Genet. 1994 Sep.
Erratum in
- Nat Genet 1994 Dec;8(4):410
Abstract
The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/Cdk-4 complexes, and is deleted or mutated in a variety of tumour types. We found allelic deletions of 9p21-p22 in 85% of pancreatic adenocarcinomas. Analysis of MTS1 in pancreatic carcinomas (27 xenografts and 10 cell lines) showed homozygous deletions in 15 (41%) and sequence changes in 14 (38%). These included eight point mutations (four nonsense, two missense and two splice site mutations) and six deletions/insertions, all accompanied by loss of the wild-type allele. Sequencing of MTS1 from primary tumours confirmed the mutations. Coexistent inactivations of both MTS1 and p53 was common and suggests that abnormal regulation of cyclin-dependent kinases may play an important role in the biology of pancreatic carcinoma.
Similar articles
- MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.
Liu Q, Yan YX, McClure M, Nakagawa H, Fujimura F, Rustgi AK. Liu Q, et al. Oncogene. 1995 Feb 2;10(3):619-22. Oncogene. 1995. PMID: 7845688 - The MTS1 gene is frequently mutated in primary human esophageal tumors.
Zhou X, Tarmin L, Yin J, Jiang HY, Suzuki H, Rhyu MG, Abraham JM, Meltzer SJ. Zhou X, et al. Oncogene. 1994 Dec;9(12):3737-41. Oncogene. 1994. PMID: 7970734 - Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM, Pearson JV, Hayward NK. Pollock PM, et al. Genes Chromosomes Cancer. 1996 Feb;15(2):77-88. doi: 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0. Genes Chromosomes Cancer. 1996. PMID: 8834170 Review. - Molecular genetics of exocrine pancreatic neoplasms.
Hahn SA, Kern SE. Hahn SA, et al. Surg Clin North Am. 1995 Oct;75(5):857-69. doi: 10.1016/s0039-6109(16)46732-0. Surg Clin North Am. 1995. PMID: 7660250 Review.
Cited by
- Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR. Pedersen KS, et al. Invest New Drugs. 2015 Aug;33(4):963-8. doi: 10.1007/s10637-015-0246-2. Epub 2015 May 8. Invest New Drugs. 2015. PMID: 25952464 Free PMC article. Clinical Trial. - Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment.
Vitorakis N, Gargalionis AN, Papavassiliou KA, Adamopoulos C, Papavassiliou AG. Vitorakis N, et al. Cancers (Basel). 2024 Aug 19;16(16):2876. doi: 10.3390/cancers16162876. Cancers (Basel). 2024. PMID: 39199647 Free PMC article. Review. - The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D, Lemke J. García-Reyes B, et al. Int J Mol Sci. 2018 Oct 18;19(10):3219. doi: 10.3390/ijms19103219. Int J Mol Sci. 2018. PMID: 30340359 Free PMC article. Review. - Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.
Ruebel KH, Jin L, Zhang S, Scheithauer BW, Lloyd RV. Ruebel KH, et al. Endocr Pathol. 2001 Fall;12(3):281-9. doi: 10.1385/ep:12:3:281. Endocr Pathol. 2001. PMID: 11740049
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous